Treatment and prevention of coronary heart disease by lowering the serum cholesterol level; third consensus 'cholesterol';Behandeling en preventie van coronaire hartziekten door verlaging van de serumcholesterolconcentratie; derde consensus 'cholesterol'

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 38, 1998, Pages 2096-2101

  Simoons, M L ^a   Casparie, A F ^b   Van Everdingen, J J E ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Erasmus Universiteit Rotterdam   (Netherlands)

^c Centraal Begeleidingsorgaan V I   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG INDICATION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LOW FAT DIET; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NETHERLANDS; PRIMARY PREVENTION;

EID: 0032547480     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Erkelens DW. Cholesterol-consensus in Nederland. Ned Tijdschr Geneeskd 1987;131:1564-9.
2. Erkelens DW. Herziening consensus cholesterol. Ned Tijdschr Geneeskd 1991,135:2337-40.
3. Jukema JW, Bruschke AVG, Boven AJ van, Reiber JHC, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40
4. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344: 633-8.
5. Vos J. Retardation of progression of coronary atherosclerosis [proefschrift]. Rotterdam: Erasmus Universiteit Roterdam, 1997.
6. Truswell AS. Review of dietary intervention studies: effect on coronary events and on total mortality. Aust N Z J Med 1994;24:98-106.
7. Nader advies inzake de richtlijn m.b.t. de vetconsumptie uit het advies Richtlijn Goede Voeding 1986. Voedingsraad. Den Haag: Voorlichtingsbureau voor de Voeding, 1991.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
9. Sacks FM, Pfeffer MA, Move LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
11. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-73.
12. Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995;274.801-6.